SSelectStock

HESTERBIOHester Biosciences Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms. It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.

2,264.90
0.62%
59Decent

Mkt Cap
₹1,929 Cr
P/E
34.6
P/B
5.3
Div Yield
0.76%
52W High
₹2,683.60
52W Low
₹1,239.30

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,928.80
P/E34.57
P/B5.32
PEG0.04
ROE %16.56
ROCE %13.90
Debt / Equity0.53
EPS65.51
Revenue Growth %40.30
Profit Growth %968.70
Dividend Yield %0.76
Promoter Holding %68.79
FII Holding %0.27
DII Holding %
Beta0.49

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on HESTERBIO — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 61%

The picture

  • Revenue growth: 40.3% YoY
  • Profit growth: 968.7% YoY
  • ROE: 16.6%
  • Price vs SMA200: above
  • Golden cross setup: SMA50 above SMA200
  • 3-month return: +10.2%

Bull case

  • Revenue growth: 40.3% YoY
  • Profit growth: 968.7% YoY
  • ROE: 16.6%
  • Price vs SMA200: above

Bear case

  • MACD: bearish
  • Price vs EMA21: below
  • 1-month return: -8.0%
  • 1-month vs NIFTY: -3.9% relative

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • MACD: bearish
  • Price vs EMA21: below

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹2,264.90
Stop Loss
₹2,124.54
risk 6.2%
Target 1 (1.5R)
₹2,475.44
+9.3%
Target 2 (3R)
₹2,685.98
+18.6%
Support (20d)
₹2,146.00
Resistance (52w)
₹2,683.60
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹140.36/share
ATR (volatility)
₹94.12
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹94.12). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental84
Technical40
Momentum63
Risk (safety)40

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78